You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
BioNTech指接種第三劑疫苗 保護率可維持在最高水平
阿思達克 07-09 16:17
BioNTech(BNTX.US)公佈,其新冠疫苗增強劑的最新進展和計劃,以應對不同的變異毒株,包括目前流行的德爾塔變異毒株。在當前進行的臨牀試驗中,BioNTech的第三劑新冠疫苗BNT162b2展現了良好的安全性和免疫原性數據。

基於迄今爲止的全部數據,BioNTech認爲,在接種兩劑BNT162b2疫苗後的6至12個月內可能需要接種第三劑疫苗,這能將疫苗的保護率維持在最高水平。

根據初始數據表明,在接種第二劑後6個月再給予第三劑BNT162b2疫苗,不僅表現出與之前一致的耐受性,同時還激發了對Beta及其他變異毒株的高度中和作用,甚至比接種完兩劑後還要高5至10倍。在近期發表的一篇《自然》論文的數據表明,在實驗室研究中,接種完第二劑BNT162b2疫苗的免疫接種者血清對Delta變異毒株具有高度中和作用。

此外,BioNTech和其合作夥伴輝瑞正在合作研發針對德爾塔變異毒株的全長刺突蛋白的改良疫苗。第一批用於試驗的mRNA疫苗已經在BioNTech位於德國美因茨的工廠開始生產,臨牀試驗預計將於8月在得到監管部門的批準後展開。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account